ValuEngine downgraded shares of Selecta Biosciences, Inc. (NASDAQ:SELB) from a hold rating to a sell rating in a research note published on Tuesday morning.

A number of other research firms also recently weighed in on SELB. Zacks Investment Research raised Selecta Biosciences from a sell rating to a hold rating in a report on Wednesday, July 12th. Canaccord Genuity set a $25.00 target price on Selecta Biosciences and gave the company a buy rating in a report on Wednesday, July 26th. Two analysts have rated the stock with a sell rating and four have assigned a buy rating to the company. The company has a consensus rating of Hold and a consensus price target of $26.00.

Shares of Selecta Biosciences (NASDAQ SELB) traded up 2.04% during trading on Tuesday, reaching $19.04. The company’s stock had a trading volume of 24,258 shares. Selecta Biosciences has a one year low of $11.95 and a one year high of $28.00. The stock’s 50 day moving average is $17.80 and its 200 day moving average is $17.80. The firm’s market cap is $420.29 million.

Selecta Biosciences (NASDAQ:SELB) last posted its earnings results on Friday, August 11th. The company reported ($0.85) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.86) by $0.01. Selecta Biosciences had a negative return on equity of 88.31% and a negative net margin of 1,277.76%. The company had revenue of $0.03 million for the quarter. On average, equities analysts forecast that Selecta Biosciences will post ($3.17) EPS for the current fiscal year.

TRADEMARK VIOLATION NOTICE: “Selecta Biosciences, Inc. (SELB) Lowered to Sell at ValuEngine” was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/09/27/selecta-biosciences-inc-selb-lowered-to-sell-at-valuengine.html.

In related news, CFO David Siewers sold 9,652 shares of the stock in a transaction dated Thursday, June 29th. The stock was sold at an average price of $20.00, for a total transaction of $193,040.00. Following the completion of the sale, the chief financial officer now owns 3,882 shares in the company, valued at $77,640. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Amir Nashat sold 147,187 shares of the stock in a transaction dated Thursday, September 21st. The stock was sold at an average price of $19.91, for a total value of $2,930,493.17. The disclosure for this sale can be found here. Insiders sold 308,463 shares of company stock worth $6,083,015 in the last ninety days.

Several large investors have recently added to or reduced their stakes in SELB. Nationwide Fund Advisors grew its position in shares of Selecta Biosciences by 224.5% during the second quarter. Nationwide Fund Advisors now owns 6,593 shares of the company’s stock worth $131,000 after purchasing an additional 4,561 shares in the last quarter. Bank of New York Mellon Corp purchased a new stake in shares of Selecta Biosciences during the first quarter worth about $211,000. The Manufacturers Life Insurance Company grew its position in shares of Selecta Biosciences by 827.0% during the second quarter. The Manufacturers Life Insurance Company now owns 11,254 shares of the company’s stock worth $224,000 after purchasing an additional 10,040 shares in the last quarter. Rhumbline Advisers purchased a new stake in shares of Selecta Biosciences during the second quarter worth about $239,000. Finally, New York State Common Retirement Fund grew its position in shares of Selecta Biosciences by 184.0% during the second quarter. New York State Common Retirement Fund now owns 12,500 shares of the company’s stock worth $248,000 after purchasing an additional 8,099 shares in the last quarter. Hedge funds and other institutional investors own 53.53% of the company’s stock.

Selecta Biosciences Company Profile

Selecta Biosciences, Inc is a clinical-stage biopharmaceutical company. The Company using its synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. The Company is engaged in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases.

Receive News & Stock Ratings for Selecta Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Selecta Biosciences Inc. and related stocks with our FREE daily email newsletter.